Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | GALK1 | P51570 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.62 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.62 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.58 |
| ▸ | MMP3 | P08254 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.58 |
| ▸ | MMP13 | P45452 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17769003 | 0.94 | KMT2A (0.64) | KMT2AMEN1POLBUSP2GALK1 | |
| SCHEMBL17779681 | 0.89 | MEN1 (0.75) | KMT2AMEN1POLBUSP2GALK1 | |
| SCHEMBL20837903 | 0.89 | MEN1 (0.75) | KMT2AMEN1POLBUSP2GALK1 | |
| SCHEMBL14652604 | 0.88 | PTPN12 (0.67) | KMT2AMEN1POLBPTPN12PTPN22 | |
| SCHEMBL20837917 | 0.88 | CISD1 (0.68) | KMT2AMEN1POLBUSP2GALK1 | |
| SCHEMBL17768881 | 0.87 | MEN1 (0.70) | KMT2AMEN1POLBUSP2GALK1 | |
| SCHEMBL18837956 | 0.86 | ADAMTS5 (0.74) | KMT2AMEN1POLBPTPN12PTPN22 | |
| SCHEMBL18837955 | 0.86 | ADAMTS5 (0.74) | KMT2AMEN1POLBPTPN12PTPN22 | |
| SCHEMBL20837918 | 0.86 | KMT2A (0.65) | KMT2AMEN1POLBUSP2GALK1 | |
| SCHEMBL17779727 | 0.85 | PTPN12 (0.62) | KMT2APTPN12PTPN22AKR1B1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2023-02-21 | — | — | US | disclosed |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2023-02-21 | — | — | US | disclosed |
| US-20220267286-A2 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-08-25 | — | — | US | disclosed |
| EP-4029859-A1 | 2-OXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-07-20 | — | — | EP | disclosed |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-02-10 | — | — | US | disclosed |
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2021-09-14 | — | — | US | disclosed |
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2021-09-14 | — | — | US | disclosed |
| US-20190092737-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 - Biomolecular Simulations Lda. (PT) | 2019-03-28 | — | — | US | disclosed |
| US-20190092737-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 - Biomolecular Simulations Lda. (PT) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | TTR, TTPA, MTPN | KMT2A 3839/4885MEN1 3201/4885POLB 3855/4885 |
| US-20220267286-A2 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | KMT2A 3693/4885MEN1 3061/4885POLB 4384/4885 |
| US-20190092737-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | KMT2A 3839/4885MEN1 3201/4885POLB 3855/4885 |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | TTR, TTPA, MTPN | KMT2A 3693/4885MEN1 3061/4885POLB 4384/4885 |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | KMT2A 3693/4885MEN1 3061/4885POLB 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.